josh_hardman

Psychedelic Bulletin #144: Otsuka to Buy Mindset; Responses to FDA Draft Guidance; Cybin to Acquire Small Pharma; Usona Publishes Phase 2 Study – Psychedelic Alpha

As we reported in June, the FDA issued its first draft guidance on clinical trials with psychedelic drugs this summer. The 14-page document presents non-binding

josh_hardman August 31, 2023

Psychedelic Bulletin #143: Trademark Filing Reveals Potential Brand Name for MDMA; DEA “Open to Considering” Special Registration for Controlled Substances via Telemedicine; Professional Practice Guidelines for PAT; Sage’s Zuranolone Rejection – Psychedelic Alpha

atai Reports Q2 2023 Earnings and Provides Ibogaine Phase 1 Update Yesterday, atai Life Sciences reported Q2 2023 financial results along with the first clinical

josh_hardman August 11, 2023

Psychedelic Bulletin #139: Kentucky Earmarks $42m for Ibogaine Studies; Reunion Announces Take-Private Deal; Compass Patents Upheld; Theories of Psychedelics’ Mechanism of Action – Psychedelic Alpha

A paper in Nature Neuroscience caused quite a stir last week. A group of researchers at University of Helsinki claim that LSD and psilocin “directly

josh_hardman June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.